Skip to main content
SpringerLink
Log in

Pharmacokinetic Optimisation of the Treatment of Cancer with High Dose Zidovudine

  • Review Article
  • Disease Management
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

The thymidine analogue zidovudine is currently used for the treatment of HIV-infected patients, as the early development of the drug as an anticancer agent yielded modest results. A comprehensive preclinical analysis, however, showed that inhibitors of de novo thymidylate synthesis, including fluorouracil and methotrexate, enhanced the antiproliferative activity of zidovudine in cancer cells. Significant inhibition of tumour growth was obtained in mice bearing human colon cancer xenografts and given intraperitoneal zidovudine 300 to 600 mg/kg weekly in combination with methotrexate 87.5 mg/kg or intraperitoneal fluorouracil 85 mg/kg, and in pharmacokinetic studies high peak drug plasma concentrations (Cmax) of zidovudine were obtained, ranging from 610.3 to 1698.8 μmol/L. In order to exploit the therapeutic activity of zidovudine, phase I and II clinical studies were designed in combination with fluorouracil and the pharmacokinetic-pharmacodynamic profile of zidovudine was investigated. Clinical responses were obtained in patients treated intravenously with bolus fluorouracil 500 mg/m2, leucovorin and short (90 to 120 minutes) infusions of high dose zidovudine (up to 10 g/m2), generating drug Cmax similar to those obtained in preclinical models.

However, in chemotherapy-pretreated patients receiving high dose zidovudine by the oral route (1 to 9 g/m2/day) or 48-hourly continuous intravenous infusion (2 to 20 g/m2/day) in combination with fluorouracil and leucovorin, treatment failures were observed despite high systemic exposure, described as the area under the plasma concentration-time curve and the occurrence of DNA strand breaks in peripheral blood mononucleated cells, the biological expression of zidovudine activity.

In conclusion, preclinical and clinical evidence suggest that the schedule of administration of zidovudine is a requisite for the expression of its activity, indicating the importance of concentration-monitored trials to optimise chemotherapy dose administration in patients. The likelihood of tumour response appears to be related to the achievement of high peak plasma concentrations of zidovudine, and constant infusions appear less likely to produce clinical results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Horowitz JP, Chua J, Noel MJ. Nucleosides v the monomesylates of 1-(2α-deoxy-β-D-lyxofuranosyl)thymines. Org Chem Ser Monogr. 1964; 29: 2076–8.

    Article  Google Scholar 

  2. Wilde MI, Langtry HD. Zidovudine: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1993; 46(3): 515–78.

    Article  PubMed  CAS  Google Scholar 

  3. Barry M, Howe JL, Ormesher S, et al. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. Br J Clin Pharmacol. 1994; 37(5): 421–6.

    Article  PubMed  CAS  Google Scholar 

  4. Kong XB, Zhu QY, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 1992; 36(4): 808–18.

    Article  PubMed  CAS  Google Scholar 

  5. Peter K, Gambertoglio JG. Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus. Clin Pharmacol Ther. 1996; 60(2): 168–76.

    Article  PubMed  CAS  Google Scholar 

  6. Mukherji E, Au JL, Mathes LE. Differential antiviral activities and intracellular metabolism of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine in human cells. Antimicrob Agents Chemother. 1994; 38(7): 1573–9.

    Article  PubMed  CAS  Google Scholar 

  7. Bebenek K, Thomas DC, Roberts JD, et al. Effects of 3′-azido-3′-deoxythymidine metabolites on simian virus 40 origin-dependent replication and heteroduplex repair in HeLa cell extracts. Mol Pharmacol. 1993; 43(1): 57–63.

    PubMed  CAS  Google Scholar 

  8. Tornevik Y, Ullman B, Balzarini J, et al. Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol. 1995; 49(6): 829–37.

    Article  PubMed  CAS  Google Scholar 

  9. Darnowski JW, Davol PA, Goulette FA. Human recombinant interferon alpha-2a plus 3′-azido-3′-deoxythymidine. Synergistic growth inhibition with evidence of impaired DNA repair in human colon adenocarcinoma cells. Biochem Pharmacol. 1997; 53(4): 571–80.

    CAS  Google Scholar 

  10. Bouayadi K, Hoffmann JS, Fons P, et al. Overexpression of DNA polymerase beta sensitizes mammalian cells to 2′,3′-deoxycytidine and 3′-azido-3′-deoxythymidine. Cancer Res. 1997; 57(1): 110–16.

    PubMed  CAS  Google Scholar 

  11. Darnowski JW, Goulette FA. 3′-Azido-3′-deoxythymidine cytotoxicity and metabolism in the human colon tumor cell line HCT-8. Biochem Pharmacol. 1994; 48(9): 1797–805.

    Article  PubMed  CAS  Google Scholar 

  12. Wagner CR, Ballato G, Akanni AO, et al. Potent growth inhibitory activity of zidovudine on cultured human breast cancer cells and rat mammary tumors. Cancer Res. 1997; 57(12): 2341–5.

    PubMed  CAS  Google Scholar 

  13. Brunetti F, Falcone A, Calabresi P, et al. 5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies. Cancer Res. 1990; 50(13): 4026–31.

    PubMed  CAS  Google Scholar 

  14. Andreuccetti M, Allegrini G, Antonuzzo A, et al. Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA induced strand breaks. Eur J Cancer A 1996; 32A(7): 1219–26.

    Article  PubMed  CAS  Google Scholar 

  15. Tosi P, Calabresi P, Goulette FA, et al. Azidothymidineinduced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo. Cancer Res. 1992; 52(15): 4069–73.

    PubMed  CAS  Google Scholar 

  16. Pressacco J, Erlichman C. Combination studies with 3′-azido-3′-deoxythimidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects. Biochem Pharmacol 1993 Dec; 46(11): 1989–92.

    Article  PubMed  CAS  Google Scholar 

  17. Tosi P, Visani G, Ottaviani E, et al. Hydroxyurea enhances 3′-azido-3′-deoxythymidine (AZT) cytotoxicity in human chronic myeloid leukemia models. Eur J Haematol. 1994; 52: 1291–5.

    Google Scholar 

  18. Marchbanks K, Dudley MN, Posner MR, et al. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. Pharmacotherapy. 1995; 15(4): 451–7.

    PubMed  CAS  Google Scholar 

  19. Posner MR, Darnowski JW, Calabresi P, et al. Oral zidovudine, continuous infusion fluorouracil, and oral leucovorin calcium: a phase I study. J Natl Cancer Inst. 1990; 82(21): 1710–4.

    Article  PubMed  CAS  Google Scholar 

  20. Posner MR, Darnowski JW, Weitberg AB, et al. High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial. Cancer. 1992; 70(12): 2929–34.

    CAS  Google Scholar 

  21. Beitz JG, Damowski JW, Cummings FJ, et al. Phase I trial of high-dose infused zidovudine combined with leucovorin plus fluorouracil. Cancer Invest. 1995; 13(5): 464–9.

    Article  PubMed  CAS  Google Scholar 

  22. Clark J, Sikov W, Cummings F, et al. Phase II study of 5-fluorouracil, leucovorin and azidothymidine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 1996; 122(9): 554–8.

    Article  PubMed  CAS  Google Scholar 

  23. Falcone A, Danesi R, Dargenio F, et al. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I–II study in previously untreated metastatic colorectal cancer patients. J Clin Oncol. 1996; 14(3): 729–36.

    PubMed  CAS  Google Scholar 

  24. Falcone A, Lencioni M, Brunetti I, et al. Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells. Ann Oncol. 1997; 8(6): 539–45.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pharmacology and Chemotherapy, Department of Oncology, University of Pisa, Via Roma 55, 56126, Pisa, Italy

    Romano Danesi

  2. Scuola Superiore S. Anna di Studi Universitari e di Perfezionamento, Pisa, Italy

    Romano Danesi & Mario Del Tacca

  3. Division of Medical Oncology, University Hospital, Pisa, Italy

    Alfredo Falcone & Pier Franco Conte

Authors
  1. Romano Danesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alfredo Falcone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pier Franco Conte
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mario Del Tacca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Romano Danesi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Danesi, R., Falcone, A., Conte, P.F. et al. Pharmacokinetic Optimisation of the Treatment of Cancer with High Dose Zidovudine. Clin Pharmacokinet 34, 173–180 (1998). https://doi.org/10.2165/00003088-199834020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199834020-00005

Keywords

Search

Navigation